Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for COVID-19 Interstitial Pneumonia
NCT04333251Phase 1Withdrawn
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Apr 2020
- Primary completion
- Sep 2021
- Modality
- Biologic
01
Overview
Phase 1, randomised, open-label trial in coronavirus disease 2019 (COVID-19) and interstitial pneumonia comparing convalescent plasma with best supportive care (2 arms). Primary endpoint: Reduction in oxygen and ventilation support at 4 weeks. Planned start Apr 2020; status: withdrawn.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)interstitial pneumonia
Beyond the preview
Go deeper on NCT04333251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333251.